Interleukin-33 and Obesity-Related Inflammation and Cancer Authors: Cameron Kowitt, Qiuyang Zhang Published: 2024 ABSTRACT Interleukin-33 (IL-33) is a cytokine belonging to the IL-1 family. It is primarily associated with type 2 immune responses. It interacts with a receptor complex on immune cells in reaction to tissue damage or cellular injury. IL-33 is crucial in immune responses and is involved in various autoimmune and inflammatory diseases. Obesity is marked by chronic inflammation and is a known risk factor for several types of cancer. Recent studies have shown that IL-33 and its receptor complex are expressed in adipose (fat) tissue, suggesting they may play a role in obesity. While inflammation connects obesity and cancer, it is not yet clear whether IL-33 contributes to cancer associated with obesity. Depending on the cellular context, inflammatory environment, expression levels, and bioactivity, IL-33 can exhibit both protumorigenic and antitumorigenic effects. This review will explore the various functions of IL-33 in the inflammation linked to obesity and its relationship with cancer. Introduction Interleukins (ILs), a specific subgroup of cytokines [1,2] mainly produced and secreted by white blood cells (leukocytes) and other types of cells in the body, are essential for regulating inflammation, tissue repair, and immune responses in healthy tissue [3]. The human genome encodes over 50 interleukins and related proteins [4]. ILs also help to maintain the balance and function of normal cells and tissues. Importantly, they serve as vital chemical signals in the immune system, significantly influencing cancer development, progression, and treatment. Based on their structural homology, ILs are categorized into several protein families, including IL-1, IL-2, IL-6, IL-10, IL-12, and IL-17 [4]. The IL-1 family is further divided into three subfamilies (the IL-1 subfamily, the IL-18 subfamily, and the IL-36 subfamily) based on the length of the N-terminal pro-pieces. The IL-1 subfamily consists of IL-1α, IL-1β, the IL-1 receptor antagonist (IL-1Ra), and IL-33 [5]. IL-33, discovered in 2005 as a new member of the IL-1 family [6] and confirmed to be a Nuclear Factor from High Endothelial Venules (NF-HEVs) [7], has been linked to several health conditions. These include asthma, airway inflammatory diseases [8], organ fibrosis [9], kidney injury [10], pediatric heart disease and transplantation [11], rheumatoid arthritis [12,13], and neurodegenerative diseases [14]. Recent research involving knowledge mapping of IL-33 has revealed its essential role as a cytokine in numerous diseases, especially allergic diseases [15]. Overweight and obesity are significant health issues affecting millions of people worldwide [16]. According to the World Health Statistics 2024 [17], approximately 2.5 billion adults aged 18 and older are classified as overweight, including over 890 million individuals living with obesity. This statistic indicates that around 43% of adults (43% of men and 44% of women) are overweight, with 16% facing obesity. Epidemiological studies consistently identify obesity as a significant risk factor for 13 types of cancer [18], which together account for 40% of all cancer diagnoses in the United States each year. Globally, approximately 4–8% of all cancers are linked to obesity [19]. However, the causal relationship between obesity and cancer remains unclear. Research indicates that IL-33 plays a critical role in obesity [20-22] and shows promising findings related to IL-33 and various cancers [23-30]. Despite this, there is a lack of research on IL-33 in the context of obesity-related cancer, particularly regarding the mechanisms by which IL-33 influences these cancers. Gaining insight into the complex connections between IL-33, obesity, and cancer could be crucial for the future management of these conditions, offering hope in the fight against these diseases. The mechanisms may involve IL-33’s regulation of specific immune cells related to obesity that contribute to disease aggressiveness. Understanding these potential pathways and targets could guide future research and therapeutic development. Therefore, the review will discuss the importance of researching obesity-related inflammation and cancer, and potential future directions. The Biology of IL-33 and Its Receptors IL-33, also known by several designations, including C9orf26 (Chromosome 9 Open Reading Frame 26), DVS27 (DVS27-Related Protein), NF-HEV (Nuclear Factor from High Endothelial Venules), DKFZp586H0523, NFEHEV, and RP11-575C20.2, is a cytokine that belongs to the IL-1 superfamily, identified explicitly as Interleukin-1 Family Member 11 (IL1F11) [6]. It was initially recognized for inducing type 2 immune responses [31,32], stimulating the production of immune cells involved in allergic reactions, and protecting against parasites. Understanding this function is crucial for comprehending its role in immune system regulation. As a tissue-derived cytokine, IL-33 has various functions; it operates as a traditional cytokine and an intracellular nuclear factor [32,33]. Its association with tissue damage or necrosis is just one facet of its complexity. In response to harmful events such as infection, injury, or inflammation, barrier tissue cells, including epithelial cells, release IL-33. The released IL-33 plays a significant role in cell communication and regulating inflammation within the body. IL-33 The IL-33 gene is located on chromosome 9p24.1 in humans and chromosome 19qC1 in mice. The human IL-33 gene consists of eight exons, with exon 1 being non-coding and exons 2-8 coding for the IL-33 protein, spanning over 42kb of genomic DNA [34]. The IL-33 protein features an N-terminal domain containing a chromatin-binding motif, a nuclear localization signal, a central domain, and a C-terminal IL-1-like cytokine domain that gives IL-33 cytokine-like properties [6,32]. The nuclear localization signal can be found within amino acids 46-67 [35]. The ability to bind to DNA determines the functions of full-length IL-33 in the nucleus as a transcription factor [36]. In mice, two different promoters initiate IL-33 gene transcription, resulting in two IL-33 transcripts (Il33a and Il33b) with differing 5′-untranslated regions but encoding the same protein. The human IL-33 mRNA encodes a protein containing 270 amino acids, while the mouse IL-33 protein consists of 266 amino acids, with a 55% similarity between the two. Research indicates that the IL-33 protein is highly conserved among mammals and is closely related to IL-18 among the IL-1 family members. IL-33 has a three-dimensional structure akin to other family members, comprised of 12 β-strands arranged in a β-trefoil fold [37,38]. The binding area of IL-33 contains a mix of polar and nonpolar regions that facilitate specific interactions between the receptor and ligand [38] (Figure 1). IL-33 Receptor The IL-33 receptor, also known as serum stimulation-2 (ST2), interleukin 1 receptorlike 1 (IL1RL1), or T1, was initially discovered in 1989 and was considered an orphan receptor until the identification of IL-33 [40,41]. There are multiple isoforms of ST2, including the membrane-bound form (ST2L) and soluble form (sST2). ST2L consists of three immunoglobulin-like motifs responsible for extracellular ligand-binding (extracellular domain), an intracellular domain, and a transmembrane domain. The extracellular domain of ST2L binds IL-33 with the assistance of the IL-1 receptor accessory protein (IL-1RAcP), which forms the transmembrane IL-33 receptor complex and recruits downstream signaling components via its Toll/interleukin-1 receptor (TIR) domain [31]. Due to its lack of intracellular and transmembrane domains, but the possession of a C-terminal sequence [42], sST2 may serve as a decoy receptor for IL-33 [43]. The IL-1R8 receptor, known as SIGIRR (single immunoglobulin IL-1R-related receptor) or TIR8 [44], acts as a negative regulator of the IL-33/ST2 signaling pathway [45]. It can dimerize with ST2L to attenuate the biological effects of IL-33 (Figure 1). IL-33/ST2 Signaling Pathway IL-33 has a dual role, acting as a nuclear factor by binding to chromatin to suppress inflammatory responses and as a cytokine released into the extracellular space in response to cell damage or mechanical injury [33]. This dual functionality underscores its crucial role in immune modulation. IL-33 exerts its cytokine activity by binding to the primary receptor, ST2, and then recruiting the accessory receptor, IL-1RAcP [6,46-48]. When IL-33 binds to the IL-33 receptor, forming the ST2L and IL-1RAcP heterodimeric complex, it initiates a signaling pathway. Following receptor binding, the TIR domain dimerization starts a pathway that includes the myeloid differentiation primary response protein 88 (MyD88), IL-1R-associated kinase 1 (IRAK1), IRAK4, tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), mitogen-activated protein kinases (MAPKs), or nuclear factor-κB (NF-κB) [34]. The intracellular signaling pathways initiated by IL-33 activate a wide array of downstream effectors. These effectors play a significant role in immune modulation and inflammatory responses [49,50], cell survival [51,52], proliferation [27], differentiation [27], apoptosis [51], angiogenesis [53], migration [54], metabolic regulation [55], and metastasis [56] (Figure 2). The Role of IL-33 in Immune Responses IL-33 and ST2 Expression in Immune Cells IL-33 is typically found in the stroma and is released by damaged or necrotic barrier cells such as endothelial and epithelial cells [57]. It is expressed at high levels in the steady-state nuclei of various cell types [34], including immune cells like resting dendritic cells (DCs) [58], activated macrophages [59], monocytes, and regulatory T cells (Tregs), as well as mast cells [59], endothelial cells, epithelial cells of barrier tissues such as the lung, intestine, skin, and fibroblasts, glial cells, astrocytes, smooth muscle cells, and platelets. IL-33 is a ubiquitous and crucial immune modulator that influences various immune cell responses [50]. It acts as an alarm signal (alarmins or danger signals), rapidly released from producing cells in response to cellular stress and injury [49] (Figure 3). ST2 is expressed in T helper 2 (Th2) cells, mast cells [42,46,60], cardiomyocytes [61], and other immune cells [57,62], including innate lymphoid cell type 2 (ILC2) [63], Tregs [64], CD4+ and CD8+ T cells [65], NKT cells [66,67], and myeloid cells, including basophils, eosinophils, and macrophages [59]. Recently, ST2 was reported to be expressed in Th1 cells [68,69], though the expression level was low and transient upon virus infection [70] (Figure 3). Il-33’s Role in Immune Responses The IL-33/ST2 pathway plays a crucial role in Th2 responses. When IL-33 activates Th2 receptors, it produces IL-4, IL-5, and IL-13. These cytokines, produced by Th2 cells, enhance chemokine production in epithelial cells [71-73]. The IL-33 gene and these cytokines are linked to Th2-related diseases, protecting against intracellular pathogens, promoting tissue repair, and contributing to chronic inflammatory diseases [74]. IL-4, a critical Th2 cytokine, is primarily produced by activated T cells, mast cells, basophils, and eosinophils. Its primary function is to transform naive CD4+T cells into Th2 cells, which initiates allergic reactions and triggers immune responses against extracellular parasites [75]. IL-4 also affects various diseases, particularly inflammatory bowel disease (IBD), where it contributes to chronic inflammation and fibrosis by promoting tissue remodeling and scarring, as well as autoimmune diseases [73]. Moreover, IL-4 supports the proliferation and survival of several cancer cells [76], being overexpressed in many human tumor types, including malignant glioma, ovarian, lung, breast, pancreatic, colon, and bladder carcinomas, which also overexpress its receptors (IL-4R) [77-79]. While several therapeutics have been developed for asthma and inflammatory diseases, their lack of efficacy has hindered further development. However, most of these treatments have shown tolerance and high safety in humans, making clinical trials for cancer therapy a possibility [76]. IL-5 is significant in developing allergic reactions and inflammation, as it regulates the production, maturation, activation, and survival of eosinophil progenitors in the blood [80]. It stimulates B lymphocytes to produce more antibodies and increases the number of eosinophils in the airways. Its primary role is to promote the activation and longevity of eosinophils, aiding their migration from the blood to the airways [81]. By encouraging the production of antibodies, particularly immunoglobulin A (IgA), which is crucial for mucosal immunity, IL-5 also influences B cell activity [81]. Additionally, IL-5 acts as a biological modifier that can enhance the immune system in cancer therapy. IL-13 is a critical factor in developing allergic inflammation [82]. It closely interacts with IL-5 and significantly impacts the airways by promoting mucus production [83]. IL-13 encourages goblet cells in the airway to produce mucus, leading to airway blockage and mucus plugging, which directly contribute to asthma [83,84]. Furthermore, IL-13 is overexpressed in various solid tumors and is associated with poor prognosis in conditions such as glioblastoma, colorectal cancer, adrenocortical carcinoma, pancreatic cancer, and breast cancer [85]. IL-33 in Obesity Obesity is linked to chronic inflammation, hormonal imbalances, insulin resistance, high insulin levels, adipokines changes, and immune function alterations [86]. Hormones such as adipokines, produced by adipose tissue, contribute to low-grade inflammation, leading to conditions like insulin resistance, diabetes, high blood pressure, and asthma, all commonly associated with obesity [87]. These adipokines can stimulate cell growth, angiogenesis, and apoptosis, all directly connected to cancer progression. Furthermore, these hormonal functions regulate the appetite, energy metabolism, and inflammation, increasing individuals’ susceptibility to cancer development and progression [88]. Adipose tissue is essential for regulating energy balance and is generally categorized into white adipose tissue (WAT) and brown adipose tissue (BAT) [89-91]. Additionally, there is a type of adipose tissue known as brown-in-white or (brite)/beige adipose tissue (BeAT), which shares the characteristics of both WAT and BAT in terms of morphology and function [92]. Research on the role of IL-33 in developing metabolic disorders such as diabetes, obesity, and cardiovascular disease has produced mixed results [22]. However, the IL-33/ST2 pathway is thought to be protective during obesity. Manipulating IL-33 expression to induce Th2 cytokines and promote macrophage polarization may offer a promising therapeutic strategy for treating or preventing type 2 diabetes in obese patients. IL-33 and ST2 Immune Cell Distribution in Adipose Tissue Immune cells and their mediators significantly regulate the metabolism, leading to a new understanding of immune regulation in metabolic processes [21]. Innate immune cells present in adipose tissue include macrophages, neutrophils, eosinophils, dendritic cells (DCs), innate lymphoid cells (ILCs), and natural killer (NK) cells [93]. In lean adipose tissue, the most common immune cells are alternatively activated macrophages (M2-like macrophages), type 2 innate lymphoid cells (ILC2s), eosinophils, Tregs, and Th2 cells [94,95]. These cells contribute to an anti-inflammatory environment. However, during obesity development and adipocyte hypertrophy, the distribution of immune cell populations changes. Most immune cells increase in adipose tissue, leading to an inflammatory state that supports insulin resistance. Exceptions to this trend include Tregs, eosinophils [21], and Th2 cells [96]. IL-33 and its receptor ST2 are abundant in adipose tissue, including preadipocytes, adipocytes, and endothelial cells [97-99]. Additionally, infiltrating immune cells that express IL-33 and ST2 are plentiful in this tissue (Figure 4). Effect of IL-33 in Adipose Tissue During Obesity Despite its increased expression in obesity, IL-33 alone cannot maintain homeostasis in obese adipose tissue. Research indicates that IL-33 treatment can improve the inflammation and metabolic changes related to obesity [22]. The role of IL-33 in immunity and the metabolism is complex, demonstrating both pro- and anti-inflammatory properties [22]. IL-33 is essential for maintaining adipose tissue homeostasis and may help protect against obesity and type 2 diabetes [100,101]. Tissue-resident stromal cells produce IL-33, supporting immune homeostasis in adipose tissue through the involvement of ILCs [101]. Furthermore, IL-33 protects against adipose tissue inflammation during obesity by inducing Th2 cytokines in WAT and promoting the polarization of WAT macrophages toward an M2, an alternatively activated phenotype [100,102,103]. This process reduces adipose mass and lowers fasting glucose levels [100]. In laboratory cultures of WAT, IL-33 stimulates the production of Th2 cytokines and chemokines while increasing the serum levels of Th2 cytokines and the number of Th2 cells in WAT. This shift affects macrophage activity in both adipose and liver tissues, reducing the chronic inflammatory response associated with obesity. Additionally, adiponectin can inhibit IL-33 signaling through AMPK-mediated feedback [104]. As obesity progresses, adipocyte hypertrophy significantly alters immune cell populations. While WAT shows increased IL-33 expression, local ILC2 levels tend to decrease [22]. This imbalance highlights the need to understand the discrepancies in regulating IL-33 at both tissue-specific and systemic levels amid obesity [22]. IFN-γ inhibits the activation and proliferation of ILC2 cells, limiting the functions of IL-33-mediated ILC2 and Tregs while promoting a Th1 immune response [97]. This suppression by IFN-γ likely facilitates inflammatory responses and reallocates metabolic resources necessary for host protection (Figure 4). Moreover, obesity is linked to an imbalance between Th17 and Treg cells, which can lead to metabolic disorders [104-106]. It also disrupts the Th1/Th2 balance, increasing the number of Th1 cells in adipose tissue while decreasing Th2 cells [107]. Although there are currently no direct studies examining how IL-33 contributes to this imbalance, these disruptions may result from reduced levels of IL-33, warranting further investigation (Figure 4). Effect of Il-33 in the Tumor Microenvironment The cytokine IL-33 has a dual role in the tumor microenvironment (TME), promoting and inhibiting tumor growth. Its protumor effects involve the accumulation of immune-suppressive cells. Conversely, IL-33 can inhibit tumor growth by interacting with the T cell receptor (TCR) and IL-12 signaling, enhancing the effectiveness of CD8+ T cells [109]. Additionally, IL-33 amplifies the responses of Th1 CD4+ T cells and Th2-type cells by acting on various immune cells, including human basophils, allergen-reactive Th2 cells, iNKT, NK cells [110], eosinophils, and ILC2 [111]. IL-33 and ST2 Immune Cell Distribution in the Tumor Microenvironment (TME) The TME varies among different types of tumors but generally includes immune cells, stromal cells, blood vessels, and the extracellular matrix [112], which actively promote cancer progression. Depending on the context, immune cells can play a pivotal role in inhibiting or supporting tumor growth [113]. ST2 is expressed in various immune cells,and IL-33 is released from damaged structural cells. IL-33/ST2 signaling is involved in numerous cancers, exhibiting both protumor and antitumor functions [114]. Understanding the diverse effects of IL-33 on immune responses in the cancer context is crucial [115]. For example, IL-33 can activate ILC2 in the lung, which promotes tumor burden by leading to innate type 2 inflammation and suppressing the production of IFN-γ and the cytotoxic functions of lung NK cells [116]. In melanoma, the overexpression of IL-33 has been shown to inhibit lung metastases by activating CD8+ T cells and NK cells [117]. Additionally, the induced expression of IL-33 in tumors can enhance anti-melanoma immune responses via IFN-γ-producing CD8+ T cells and NK cells [118], presenting potential opportunities for cancer therapy. Eosinophils [119] and DCs [120] may also mediate the anti-melanoma effects of exogenous IL-33. In breast cancer, IL-33 secreted by cancer-associated fibroblasts enhances ILC2 and Th2 type responses, induces the TCR-independent secretion of IL-13, and recruits immunosuppressive granulocytes [121]. Furthermore, IL-33 activates the intrinsic signaling pathway in Treg cells, which is necessary for their immunosuppressive action in cancer [122]. When combined with the pro-inflammatory cytokine IL-12, IL-33 amplifies the production of the Th1 cytokine IFN-γ [109]. Overall, the IL-33/ST2 signaling pathway significantly influences the TME in cancer by impacting immune effector cells and regulating the recruitment of cells that either promote or inhibit tumor growth [123]. Due to its immunomodulatory properties, IL-33 has the potential to synergize with various cancer therapies, including immune checkpoint blockade and chemotherapy. This information focuses on the effects of IL-33/ST2 on immune cells and stroma cells within the TME [111] (Figure 5). Effect of Il-33 on Neutrophils, Eosinophils, Mast Cells, and Basophils Depending on the specific disease context, IL-33 affects innate immune cells, including neutrophils, eosinophils, mast cells, and basophils [124]. It can promote inflammatory or regulatory responses in neutrophils and eosinophils, contributing to tissue repair or immunosuppression [125]. Studies have demonstrated that IL-33 directly influences murine neutrophils, enhancing their recruitment and activation in inflamed tissues [125]. In cancer, IL-33-driven neutrophils are associated with pro-inflammatory and regulatory functions. Eosinophils, which play a vital role in the host defense against parasites and infections, are activated by IL-33 for allergic reactions and tissue repair [125]. In the context of cancer, Il-33 is linked to using eosinophils for antitumor effects, such as inhibiting growth and preventing metastasis. IL-33-activated eosinophils express higher effector molecules, including the eosinophil cationic protein (ECP), eosinophil peroxidase (EPX), and granzymes. They also express integrin CD11b/CD18, which forms immune synapses that facilitate the killing of tumor cells in vitro and in vivo [126]. Mast cells, which respond to IL-33, accumulate in tumors and their microenvironment during disease progression [127]. They are involved in tumor growth, with their mediators exhibiting both pro- and antitumorigenic roles in various human cancers [128]. Activating mast cells and basophils by IL-33 may influence tumor progression by modulating cytokine release and triggering immune complex activation. Recent studies indicate that tumorinfiltrating mast cells activated by IL-33 secrete IL-2 and promote the expansion of ICOS+ Tregs, which contributes to gastric cancer progression [129]. Basophils, produced in the bone marrow, are white blood cells needed for maintaining a healthy immune system. Abnormal levels of basophils can indicate conditions such as inflammation and hyperthyroidism. IL-33 can activate both murine and human basophils, increasing the production of histamine and cytokine in vitro and promoting their expansion in vivo [130-133]. However, a limited understanding of the relationship between basophils, cancer, and IL-33 regulation remains [125,134]. Effect of Il-33 on Macrophages and Dendritic Cells Macrophages and DCs play crucial roles in the innate immune system, particularly regarding tumor immunity and immunology [135]. IL-33 is a crucial regulator of the activity of DCs and macrophages within the TME, displaying both pro- and antitumor effects [135]. Notably, IL-33 is essential for promoting M2-like polarization in macrophages, a process associated with immunosuppressive and tumor-promoting properties [135]. This polarization involves the release of anti-inflammatory cytokines and the stimulation of tumor angiogenesis, invasion, and metastasis [134,136]. In addition to its effects on macrophages, IL-33 also influences DCs. DCs activated by IL-33 demonstrate increased cytokine production and enhanced antigen presentation capabilities, which promote T cell activation and bolster antitumor immune responses. However, conflicting studies regarding IL-33’s influence on DC-mediated antitumor immunity suggest that its function in DCs may vary based on its location within the body [134]. This discrepancy highlights the need for further research in this area. Moreover, with the assistance of dectin1-activated DCs, IL-33 can induce Th9 cell differentiation and enhance the antitumor efficacy [137,138]. While some studies indicate that IL-33 improves T cell activation and DC-mediated antigen presentation, others argue that IL-33 may lead DCs to acquire tolerogenic characteristics, inhibiting the immune system’s ability to combat cancer [134]. Effect of Il-33 on CD8+ T, NK, and NKT Cells Several studies have demonstrated that IL-33 expression is positively correlated with the recruitment of CD8+ T cells and NK cells within the TME. CD8+ T, NK, and NKT cells are effective tumor-killer cells with many phenotypes and functions relevant to antitumor immunity [139]. IL-33 directly activates NK and NKT cells, leading to the production of IFN-γ and the promotion of Th1 immunity [140]. It also targets immunoregulatory invariant NKT (iNKT) cells to enhance their activation state [66]. This activation induces the production of IFN-γ and promotes Th1 immunity in both human and mouse NK cells [138]. When combined with IL-12, IL-33 further enhances NK cell activation, improving their ability to destroy tumor cells through cytotoxicity. In preclinical models, IL-33 has been shown to support the recruitment and activation of cytotoxic NK cells in the TME, which hinders the formation of metastasis and suppresses tumor progression [134]. However, it is crucial to note that conflicting reports are suggesting that, in specific tumor microenvironments, IL-33/ST2 signaling may hinder NK cell activation. This underscores the need to consider the context-dependent effects of IL-33 on NK cell-mediated antitumor responses. Such considerations should be a key focus in future research and clinical applications, emphasizing the necessity for further investigation and careful application [27]. Effect of Il-33 on Myeloid-Derived Suppressor Cells IL-33 significantly affects myeloid-derived suppressor cells (MDSCs), which are critical mediators of immune suppression within the tumor [23]. MDSCs play a crucial role in cancer by helping tumors evade the immune system and accelerating disease progression [23]. IL-33 partially regulates the function and development of MDSCs within the TME [23]. In this environment, IL-33 reduces apoptosis and supports MDSC survival by inducing autocrine secretion of GM-CSF. This creates a positive feedback loop that promotes MDSC accumulation [23]. The increase and promotion of MDSCs are linked to tumor development and heightened immunosuppression due to IL-33. However, studies have shown that, in some contexts, IL-33 can inhibit the growth of MDSCs and decrease their immunosuppressive capabilities, resulting in enhanced antitumor immune responses and tumor regression [23,134]. Effect of Il-33 on T Helper Cells IL-33 plays a significant role in regulating the development and function of CD4+ T cells, including CD4+ T helper (Th) cells and CD4+ Treg cells [124,141]. Early in T cell activation, IL-33 stimulates Th1 differentiation and works alongside IL-12 to enhance Th1 polarization [124,141]. Moreover, IL-33 may promote Th1 cell differentiation depending on the presence of IL-12 and ST2 [141]. MyD88 is essential for IL-33, as well as IL-12-induced Th1 cell development and the production of IFN-γ [141]. Additionally, IL-33 fosters the proliferation of Th cells that produce IL-9 (Th9), strengthening immune responses against tumors. Conversely, IL-33 signaling encourages the proliferation of suppressive CD4+ Foxp3+ GATA3+ Treg cells, especially in tumor-specific environments high in IL-33 [60,141]. These Treg cells have a complex regulatory role, which may limit antitumor immunity while exhibiting suppressive solid activities [134]. In preclinical models, IL-9-producing Th9 cells are vital for initiating robust immune responses against tumors and promoting tumor regression. Research on T cell differentiation indicates that IL-33 has context-dependent effects on Th1- and Th2-skewing, reflecting the complexities of immune system regulation [134,141]. The unique cues from the tumor microenvironment can influence how these signaling pathway function in Th cell development. Th17 cells play a significant role in inflammation and are implicated in various autoimmune diseases [142]. Their activity is influenced by different molecular signals within the TME [143], which affects their proliferation, differentiation, metabolic reprogramming, and phenotypic transformation, resulting in a dual impact on tumor progression [143]. Recent studies suggest that Th17 cells accumulating in the small intestine during inflammation express the IL-33 receptor (ST2), with intestinal epithelial cells (IECs) being the primary source of IL-33 [144]. When exposed to IL-33, both mouse and human Th17 cells exhibit reduced expression of pro-inflammatory genes and increased IL-10. This anti-inflammatory cytokine can limit intestinal inflammation and control previously activated pathogenic Th17 cells. The findings indicate that, in response to IL-33, Th17 cells acquire immunosuppressive properties. The IL-33/ST2 axis is likely crucial in regulating pathogenic Th17 cells in the small intestine, helping to maintain homeostasis [144]. Effect of Il-33 on CD4+ Treg Cells and in Tumor Immunity IL-33 signaling influences effector Th cells and the growth and activity of Treg cells within the TME. Research shows that suppressive CD4+ Foxp3+ GATA3+ Treg cells proliferate in response to ST2/IL-33 signaling, both in vivo and in vitro, which aids in immunosuppression and tumor immune evasion [134]. IL-33 signaling promotes the generation of IL-2 by DCs and facilitates TGF-β1-mediated Treg cell development, leading to the expansion of ST2+ Treg cells [134,145]. These IL-33-expanded Treg cells are present in both immune and non-immune tissues and exert a strong suppressor effect, creating an immunosuppressive tumor microenvironment [146]. In the lungs, CD4+Foxp3+ Treg cells are expressed the IL-33 receptor ST2 [147]. When exposed to IL-33, Treg cells increase their canonical Th2 transcription factor GATA3 and ST2 expression levels, along with producing type 2 cytokines. This exposure leads to a significant shift in the immune response, causing Treg cells to lose their ability to suppress effector T cells [147]. Furthermore, IL-33 has been implicated in promoting the accumulation and maintenance of ST2+ Treg cells in inflamed tissues, exacerbating immunosuppression and facilitating tumor progression [134]. The complex interaction between IL-33 signaling and CD4+ T cell subsets underscores its significance in supporting antitumor immune responses [134]. By stimulating the growth of suppressive Treg cells and influencing Th cell differentiation, IL-33 regulates adaptive immune responses within the tumor. The crucial role of IL-33 in promoting Treg cell expansion highlights its potential as a target for therapeutic intervention in cancer immunotherapy, emphasizing the importance of understanding and utilizing IL-33 in cancer treatment [138]. IL-33-Expressing Cells and the Effects of IL-33 on Non-Immune Cells in the TME The impact of IL-33 is influenced by the types of cells that produce it within the TME. These cells include immune cells, stromal cells, non-tumor epithelial cells, and transformed (epithelial) tumor cells, which are significant sources of IL-33 in the TME [57]. Fibroblasts, in particular, play a crucial role; their dysregulation during cancer creates an environment that fosters tumor growth by remodeling the extracellular matrix and releasing pro-angiogenic factors [148,149]. Research has shown that cancer-associated fibroblasts can induce IL-33 production [150]. Stromal cells have also been identified as a primary source of IL-33 among non-immune cells, and IL-33 derived from these cells has been linked to tumor metastasis [115,148,151,152]. The analysis of The Cancer Genome Atlas (TCGA) data and mRNA sequencing from the TCGA revealed that IL-33, expressed in endothelial and epithelial cells, could further contribute to tumor immune responses [115,151]. Moreover, IL-33 produced by non-tumor epithelial cells has been shown to drive colorectal cancer tumorigenesis in APCMin/+ mice, which serve as an excellent model for colorectal tumors due to a mutation in the APC gene, a significant tumor-suppressor gene in the Wnt signaling pathway [153]. The expression of IL-33 changes during tumor progression. At the same time, it is highly expressed in normal epithelial cells, and tumor development leads to its downregulation in epithelial cells and upregulation in the tumor stroma and serum [114]. Therapeutic overexpression of IL-33 in tumor epithelial cells promotes type 1 antitumor immune responses through CD8+ T cells and NK cells. In contrast, IL-33 from tumor stroma fosters immune tolerance and suppression via Tregs and MDSCs [114]. Overall, IL-33 expression is context-dependent. In some tumors, IL-33 is highly expressed in normal epithelial cells but downregulated in cancer cells in advanced conditions [114,154,155]. Conversely, IL-33 or ST2 protein expression levels in other tumors increase in cancerous lesions compared to matched normal tissues [123,156,157]. Discussion of IL-33 and Obesity-Associated Cancer Recent scientific research has confirmed a clear connection between a high BMI and the risk of developing various types of cancer [19,30]. While obesity itself may not directly cause cancer, it increases the likelihood of developing aggressive, fast-growing forms of cancer that are more challenging to treat. Therefore, addressing obesity is vital for reducing the risk of cancer-related complications [19]. Research suggests that inflammation is connected to obesity and cancer [158]. IL-33 plays multiple roles in adipose tissue and the TME. However, studies explicitly examining the direct effects of IL-33 in obesity-related cancer are limited. Given its significant role in both obesity and cancer, more research is needed to fully understand IL-33’s potential in regulating obesity and decreasing cancer risk. Current findings are promising and may indicate a new pathway for disease management. Future research should investigate how IL-33 impacts fat tissue function, energy expenditure, and immune modulation to identify potential therapeutic targets. It is also crucial to further explore the influence of immune cells on both antitumor and protumor processes in different types of obesity-related cancers. Targeting IL-33 signaling pathways and their downstream effects could help regulate obesity while exhibiting antitumor properties. Additionally, IL-33’s anti-inflammatory characteristics provide another possible intervention avenue, as chronic inflammation is a critical factor in obesity and a significant contributor to cancer development. Therapies based on IL-33 could reduce obesity-induced inflammation in fat tissue and other affected organs, subsequently lowering cancer risk. Moreover, conducting clinical trials and utilizing personalized medicine approaches are essential to evaluating the safety and effectiveness of IL-33-based treatments. This process involves developing tailored treatment plans considering each patient’s unique risk factors and metabolic profiles. A comprehensive understanding of IL-33’s role in immune regulation and metabolism is critical for harnessing it as a therapeutic target to manage obesity and mitigate cancer risk. Collaboration among scientists, clinicians, and industry partners is vital for expanding our understanding of IL-33 biology and translating scientific discoveries into practical applications. Conclusions and Prospects Research into the various roles of IL-33 in immune modulation, obesity, and cancer is essential. The complex interactions between the IL-33/ST2 axis in adipose tissue and the tumor microenvironment (TME) deserve a thorough investigation, especially concerning obesity-related tumors. Given IL-33’s importance in both obesity and cancer, much remains to be explored regarding the roles of the IL-33/ST2 pathway in various types of obesity-related cancers and their responses to treatment. Both animal and human studies are necessary to fully understand how the IL-33/ST2 axis contributes to these cancers.